The Redemption of Celecoxib
What if the drug we ran from was safer than the one we ran to?
In the early 2000s, the “Coxib Crisis” sent shockwaves through medicine. The withdrawal of Vioxx (rofecoxib) created a cardiovascular ghost that haunted every remaining drug in its class. For years, clinicians shied away from celecoxib (Celebrex), fearing that its selective COX-2 inhibition was a heart attack waiting to happen. Many pivoted instead toward what they perceived as a safer middle ground for moderate pain: tramadol.
That pivot, we now know, was a mistake—one with consequences that are still playing out in hospitals and clinics daily across the country.
What the PRECISION Trial Actually Showed
The landmark PRECISION trial, published in the New England Journal of Medicine, finally cleared the air. After tracking over 24,000 patients who were at elevated cardiovascular risk, researchers found that moderate doses of celecoxib carried no greater cardiovascular risk than alternatives like ibuprofen or naproxen. In fact, celecoxib demonstrated significantly fewer gastrointestinal and renal complications than its comparators.
Let that land for a moment: the drug we spent a decade avoiding turned out to be at least as safe as the alternatives—and gentler on the gut and kidneys to boot.
Yet despite this redemption, celecoxib remains underutilized. Many clinicians, still operating on outdated cautionary tales, never updated their prescribing habits. And the drug that filled the void? An opioid that was never as gentle as advertised.
Tramadol: A Wolf in Sheep’s Clothing
Tramadol was long marketed as a “kinder, gentler” opioid—a Schedule IV drug with a unique dual mechanism that many believed bypassed the heavy risks of traditional narcotics. That perception drove its prescribing volume to staggering heights. According to the DEA’s National Prescription Audit, approximately 27 million tramadol prescriptions were dispensed in the United States in 2024 alone, making it one of the most prescribed opioids in the country.
Now, a major systematic review is challenging every assumption that drove that volume.
Published in October 2025 in BMJ Evidence-Based Medicine, researchers conducted a meta-analysis of 19 randomized clinical trials enrolling over 6,000 participants. Their findings were sobering on every front.
On efficacy, tramadol’s pain reduction was modest at best, falling below the threshold most clinicians would consider meaningful relief. On safety, the analysis revealed a doubling of serious adverse events compared to placebo, driven primarily by cardiac events including chest pain, coronary artery disease, and congestive heart failure. And on the question of addiction, real-world data continues to show that tramadol’s dependency profile can be strikingly similar to more potent opioids like oxycodone.
The conclusion? The potential harms of tramadol for pain management likely outweigh its limited benefits.
The Irony We Can’t Ignore
So we avoided a non-addictive anti-inflammatory over unproven cardiovascular fears, only to embrace an addictive opioid that may carry those very same cardiovascular risks—plus the added burden of dependency, withdrawal, and overdose potential.
It is one of the most consequential prescribing miscalculations of the last two decades. And with tens of millions of tramadol prescriptions still going out the door each year, the cost of inertia isn’t theoretical—it’s measured in cardiac events, new dependencies, and patients whose pain was never adequately managed in the first place.
Correcting the Course
The good news? It’s not too late to change. The evidence is now unambiguous—returning to evidence-based celecoxib and NSAID use, as part of a broader multimodal strategy—can provide patients with effective pain relief that doesn’t compromise their heart or their future.
Programs built around Enhanced Recovery protocols are already proving this works. At Goldfinch Health, we help post-surgery patients every day to achieve excellent pain control through opioid-minimized pathways. This reduces unnecessary opioid exposure before it starts, for patients, families, and communities. The approach isn’t radical. It’s simply what the science has been telling us, if we’re willing to listen.
The ghost of Vioxx haunted celecoxib for far too long. It’s time to let the evidence—not the fear—guide prescribing. The patients we collectively serve deserve it.